Drug · CHEMBL1702

ATOMOXETINE HYDROCHLORIDE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. ATOMOXETINE HYDROCHLORIDE. Drugs and targets, record CHEMBL1702. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1702

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: ATOMOXETINE HYDROCHLORIDE; ChEMBL
ChEMBL ID: CHEMBL1702; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Strattera; ChEMBL
Other names: (r)-(-)-tomoxetine hydrochloride, Atomoxetine (as hydrochloride), Atomoxetine hcl, LY-139603, NSC-759104, Tomoxetine, Tomoxetine hydrochloride; ChEMBL
Parent form: ATOMOXETINE, CHEMBL641; Drugs and targets
InChIKey: LUCXVPAZUDVVBT-UNTBIKODSA-N; ChEMBL
Open Targets' highest stage: Approval, for 4 of its 4 diseases, from DailyMed, FDA and PMDA; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
SLC6A2	Sodium-dependent noradrenaline transporter	Norepinephrine transporter inhibitor	INHIBITOR	https://conductscience.org/library/genes/6530

Source ChEMBL

Diseases4

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
attention deficit-hyperactivity disorder	Approval	DailyMed, FDA and PMDA	30	15	https://conductscience.org/library/drugs?q=MONDO_0007743
Alzheimer disease	Approval	PMDA	2	1	https://conductscience.org/library/drugs?q=MONDO_0004975
Huntington disease	Approval	PMDA	1	0	https://conductscience.org/library/drugs?q=MONDO_0007739
atopic eczema	Approval	PMDA	1	0	https://conductscience.org/library/drugs?q=MONDO_0004980

Source Open Targets

Trials17

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01244490	Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)	Phase 3	338	2014-07-14	atomoxetine hydrochloride	Its name	ClinicalTrials.gov
NCT01106430	Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate	Phase 3	267	2013-06-24	atomoxetine hydrochloride	Its name	ClinicalTrials.gov
NCT00191386	Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)	Phase 3	228	2010-11-10	atomoxetine hydrochloride	Its name	ClinicalTrials.gov
NCT00568685	Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)	Phase 3	153	2009-12-14	atomoxetine hydrochloride	Its name	ClinicalTrials.gov
NCT00190736	Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)	Phase 4	440		atomoxetine hydrochloride	Its name	ClinicalTrials.gov
NCT00190879	Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder	Phase 4	440		atomoxetine hydrochloride	Its name	ClinicalTrials.gov
NCT00191659	Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents	Phase 3	200		atomoxetine hydrochloride	Its name	ClinicalTrials.gov
NCT00191009	Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease	Phase 2/3	124		atomoxetine hydrochloride	Its name	ClinicalTrials.gov
NCT00485459	Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD	Phase 3	106		atomoxetine hydrochloride	Its name	ClinicalTrials.gov
NCT00386581	Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder	Phase 3	105		atomoxetine hydrochloride	Its name	ClinicalTrials.gov

1 to 10 of 17

See all 17 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Lisdexamfetamine Dimesylate vs Atomoxetine Hydrochloride: serious adverse events	0 of 128	0 of 134	262	NCT01106430

Source Trial comparisons

Papers from its trials13

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30096196	RESULT	1	PubMed
27238063	RESULT	1	PubMed
25928870	RESULT	1	PubMed
25453486	RESULT	1	PubMed
23959815	RESULT	1	PubMed
22146580	RESULT	1	PubMed
18815438	RESULT	1	PubMed
38824626	DERIVED	1	PubMed
25999292	DERIVED	1	PubMed
25038977	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL1702

GET https://conductscience.org/api/drugs/v1/CHEMBL1702/targets

API reference For AI assistants